Advertisement

Volume 133, Issue 17

 

 

April 25, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Critical insights into the structure and function of ADAMTS13. See the article by Zhu et al.

Epigenetic control of early dendritic cell lineage specification by the transcription factor IRF8 in mice
In a Plenary Paper, the investigators demonstrate that IRF8 expression delineates a subset of lymphoid-primed multipotent progenitors biased towards the generation of classical type 1 dendritic cells (DCs) by epigenetically priming the precursors for the expression of DC lineage genes.


The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
The authors report that a favorable cytokine profile induced by lymphodepletion predicts durable remissions in patients with aggressive non-Hodgkin lymphoma treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.


Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation

and

Exploring the “minimal” structure of a functional ADAMTS13 by mutagenesis and small-angle X-ray scattering
Investigators using complementary approaches report critical insights into the structure and function of ADAMTS13. Their studies reveal interactions that allosterically regulate the proteolytic activity of ADAMTS13 on von Willebrand factor.


A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
Voxelotor (GBT440) binds to the a-globin chain of hemoglobin and increases hemoglobin-oxygen affinity, thereby decreasing the polymerization tendency of deoxygenated sickle hemoglobin. The results of this phase 1/2 study of voxelotor in patients with sickle cell disease show a median 1 g/dL increase of hemoglobin concentration and a decrease of markers of hemolysis.


Review Series: Transfusion Medicine
This series of reviews provides an update on the prevention, diagnosis, and treatment of transfusion reactions and highlights the impact of genomics and big data analytics on transfusion medicine.


The articles in this review series include the following:


View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.